title: Protective efficacy of N-(2-hydroxyphenyl) acetamide against adjuvant-induced arthritis in rats.
abstract: Rheumatoid arthritis is a chronic inflammatory joint disease characterized by synovial proliferation and tissue destruction. Proinflammatory cytokines like interleukin-1beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) play a key role in the disease process and elevate energy expenditure, which further increases the joint pain and stiffness. To explore the effects of N-(2-hydroxyphenyl) acetamide (NA-2) on the development of arthritis, clinical signs, histopathology of knee joints, nociception analysis, and the serum levels of IL-1β and TNF-α were monitored. Arthritis was induced by intradermal administration of heat-killed adjuvant Mycobacterium tuberculosis H37Ra in rats. NA-2 and indomethacin treatments were started in their respective group on the same day when adjuvant was administered. Experiments were terminated when arthritic score of 4 was observed in arthritic control group. NA-2 (5 mg/kg) treatment significantly ameliorated the disease severity. Reduction in body weight and increase in paw oedema were significantly reversed in arthritic animal receiving NA-2. The nociceptive sensation was also inhibited in the NA-2 treated arthritic rats. Remission was associated with improved histology and significant decreased expression of serum proinflammatory cytokines (P < 0.05 for IL-1β and TNF-α). Based on our observations, it can be suggested that NA-2 possesses promising anti-arthritic property, and it can be used as a therapeutic agent for arthritis.
authors: Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center of Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan.
authors: Kahkashan
authors: K
authors: Perveen
authors: Farina
authors: F
authors: Hanif
authors: Huma
authors: H
authors: Jawed
authors: Shabana U
authors: SU
authors: Simjee
mesh_terms: D000083:Acetanilides / Q000008:administration & dosage*; D000276:Adjuvants, Immunologic; D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage; D018771:Arthralgia / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology*; D001168:Arthritis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology*; D016207:Cytokines / Q000097:blood; D005260:Female; D053583:Interleukin-1beta / Q000097:blood*; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
chemical_list: D000083:Acetanilides; D000276:Adjuvants, Immunologic; D018501:Antirheumatic Agents; D016207:Cytokines; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; C047799:2-hydroxyacetanilide
references: J Rheumatol. 1998 Oct;25(10):1945-52
references: 9779848
references: Neurosci Res. 1989 Aug;6(6):569-72
references: 2797508
references: Arthritis Rheum. 1998 Jun;41(6):951-62
references: 9627005
references: EMBO J. 1991 Dec;10(13):4025-31
references: 1721867
references: Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):7-16
references: 11357166
references: Adv Drug Deliv Rev. 2006 May 20;58(2):323-42
references: 16626837
references: Arthritis Res. 2000;2(3):189-202
references: 11094428
references: Pain. 1987 Feb;28(2):201-222
references: 3547255
references: J Clin Invest. 1996 Jun 1;97(11):2672-9
references: 8647962
references: Nat Rev Drug Discov. 2003 Jun;2(6):473-88
references: 12776222
references: Pain. 1983 Jun;16(2):109-110
references: 6877845
references: APMIS. 1992 Jan;100(1):1-9
references: 1536716
references: Science. 2000 Jun 9;288(5472):1765-9
references: 10846153
references: ILAR J. 1999 Jun;40(3):111-118
references: 11406689
references: Cell Mol Life Sci. 2000 Sep;57(10):1457-70
references: 11078023
references: Annu Rev Immunol. 1996;14:397-440
references: 8717520
references: J Ethnopharmacol. 2007 Mar 1;110(1):39-48
references: 17049776
references: J Ethnopharmacol. 2005 Oct 3;101(1-3):104-9
references: 15970410
references: Rheumatology (Oxford). 2006 Jun;45(6):669-75
references: 16567358
references: Arthritis Rheum. 1997 Mar;40(3):534-9
references: 9082942
references: Pain. 1993 Oct;55(1):5-54
references: 8278210
references: Arthritis Rheum. 2002 Jul;46(7):1926-36
references: 12124878
references: Clin Exp Immunol. 2004 Jul;137(1):65-73
references: 15196245
references: Pain. 2001 Aug;93(2):107-114
references: 11427321
references: J Rheumatol Suppl. 2002 Sep;65:3-9
references: 12236620
references: Arthritis Care Res. 1996 Apr;9(2):151-6
references: 8970274
references: J Clin Invest. 1994 Mar;93(3):1095-101
references: 8132748
references: Arthritis Rheum. 2000 Oct;43(10):2143-51
references: 11037873
references: N Engl J Med. 2004 Jun 17;350(25):2591-602
references: 15201416
references: N Engl J Med. 1990 May 3;322(18):1277-89
references: 2271017
references: Am J Med. 1985 Jan 21;78(1A):1-5
references: 3918440
references: Nat Med. 1995 Jan;1(1):27-31
references: 7584949
references: J Exp Med. 1996 Sep 1;184(3):883-91
references: 9064348
references: N Engl J Med. 2001 Mar 22;344(12):907-16
references: 11259725
references: J Neurosci. 1999 Sep 1;19(17):7670-8
references: 10460273
references: Arthritis Rheum. 1992 Jul;35(7):729-35
references: 1622409
references: Nat Rev Immunol. 2007 Mar;7(3):191-201
references: 17290298
references: J Bone Miner Res. 2005 Oct;20(10):1756-65
references: 16160733
references: Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii84-6
references: 12379632
references: Inflammation. 2012 Aug;35(4):1348-56
references: 22389056
references: J Clin Invest. 1994 Jun;93(6):2379-86
references: 8200971
references: Drugs Aging. 1998 May;12(5):377-90
references: 9606615